- Pharmaceutical companies
- Europe
- Lithuania
- AstraZeneca
AstraZeneca in Lithuania
E-mail: astrazeneca.lithuania@astrazeneca.com
Web: https://www.astrazeneca.com/
Address:
-
UAB „AstraZeneca Lietuva“
Spaudos g. 6-1, LT-05132, Vilnius, Lietuva
Phone: +370 5 266 0550
Other AstraZeneca's locations around the world
Europe
North America
Asia
Africa
Oceania
Clinical Trials sponsored by AstraZeneca
-
AstraZenecaAstraZeneca K.K.CompletedNonalcoholic SteatohepatitisUnited States, Italy, Thailand, Germany, Brazil, China, Malaysia, Taiwan, Chile, Spain, Japan, Hong Kong, Argentina, India, Mexico, Vietnam, Singapore, Philippines, Peru, Colombia, South Korea, Turkey (Türkiye)
-
AstraZenecaAstraZeneca K.K.CompletedDyslipidemiaUnited States, Canada, Spain, Hungary, Czechia, Denmark, Slovakia, Japan
-
AstraZenecaNot yet recruitingNon-small Cell Lung Cancer (NSCLC)United States, France, Italy, Canada, Brazil, China, Australia, Argentina, Poland, Singapore, South Korea
-
AstraZenecaNot yet recruiting
-
AstraZenecaNot yet recruitingNSCLC | Non-small Cell Lung Cancer | Stage I-II Unresected NSCLC
-
AstraZenecaRecruitingGastric Cancer | Gastroesophageal Junction CancerGreece
-
AstraZenecaNot yet recruitingChronic Rhinosinusitis With Nasal PolypsJapan
-
AstraZenecaRecruitingObesity or OverweightArgentina, Italy, Germany, United States, France, Australia, China, Poland, Taiwan, Bulgaria, Canada, India, Brazil, Czechia, Japan, South Korea
-
AstraZenecaRecruitingDiabetes Mellitus, Type 2 | Obesity or OverweightSpain, Argentina, United Kingdom, United States, Germany, India, Poland, China, Taiwan, Hungary, Canada, Slovakia, Japan, Australia, Chile, South Korea
-
AstraZenecaNot yet recruitingHepatic ImpairmentUnited States
About AstraZeneca
We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Our purpose and values help explain why we exist, what we hope to accomplish, the behaviours we value, how we will achieve our goals, and the promise of our brand to our stakeholders.